NB-001

DB12716InvestigationalSmall molecule

NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.

Mechanism: NB-001 is developed by NanoBio with an additional pharmaceutical treatments utilizing the NanoStat antimicrobial technology for fungal, viral and bacterial infections of the skin and mucous membranes. In addition to Herpes labialis, clinical trials has begun with NanoTxt, which is a topical treatment for nail fungus (onychomycosis). NanoBio's product has the potential to be the first topical treatment for nail fungus with efficacy similar to systemic medications.
Curator reviewed
Formula / weight: C₁₂H₂₀N₆O · 264.333 g/mol (avg)
Code names: HTS-09836 · NB-001

Resolves to

Compound

Structure

InChIKeyCVPTTZZCRDVGSU-UHFFFAOYSA-NSMILESNC1=C2N=CN(CCNCCCCCO)C2=NC=N1

Targets

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with NB-001, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.